Prosecution Insights
Last updated: April 19, 2026
Application No. 18/795,360

SURGICAL NAVIGATION SYSTEM WITH FLAT PANEL REGISTRATION FIXTURE

Non-Final OA §DP
Filed
Aug 06, 2024
Examiner
GAWORECKI, MARK R
Art Unit
2884
Tech Center
2800 — Semiconductors & Electrical Systems
Assignee
Globus Medical Inc.
OA Round
1 (Non-Final)
91%
Grant Probability
Favorable
1-2
OA Rounds
2y 1m
To Grant
98%
With Interview

Examiner Intelligence

Grants 91% — above average
91%
Career Allow Rate
1025 granted / 1128 resolved
+22.9% vs TC avg
Moderate +7% lift
Without
With
+6.6%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
23 currently pending
Career history
1151
Total Applications
across all art units

Statute-Specific Performance

§101
5.7%
-34.3% vs TC avg
§103
35.8%
-4.2% vs TC avg
§102
24.4%
-15.6% vs TC avg
§112
25.5%
-14.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1128 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 9-20 (“present claims”) are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 9, 9, and 11-20, respectively of U.S. Patent No. 12,161,427 (“patent claims”). Although the claims at issue are not identical, they are not patentably distinct from each other because they would have been anticipated by the patented claims. Present claim: Patent claim: 9. A registration fixture for registration of a medical image to a three-dimensional tracking space comprising: a base frame adapted to be mounted to an x-ray medical imaging device; an orientation plate attached to the base frame comprising a first set of radiopaque markers arranged along a plurality of radial lines extending from a center location and at least three of the radiopaque markers are arranged along each radial line of the plurality of radial lines; and a registration plate attached to the base frame and spaced apart from the orientation plate, the registration plate having a second set of radiopaque markers. 10. The registration fixture of claim 9, wherein the second set of radiopaque markers are arranged along a circle. 9. A registration fixture for registration of a medical image to a three-dimensional tracking space comprising: a base frame adapted to be mounted to an x-ray medical imaging device; an orientation plate attached to the base frame and having a first set of radiopaque markers arranged along at least four radial lines which extend from a center location, the radial lines are angularly spaced apart about the center location, and at least three of the radiopaque markers are arranged along each of the radial lines; and a registration plate attached to the base frame and spaced apart from the orientation plate, the registration plate having a second set of radiopaque markers arranged along a circle. Present claims 11-20 appear to directly respond to Patent claims 11-20. Allowable Subject Matter Claims 1-8 are allowed. Claims 9-20 would be allowable if rewritten or amended to overcome the Double Patenting rejection(s) set forth in this Office action. The following is a statement of reasons for the indication of allowable subject matter: Wan (US 2022/0346831 A1) discloses a system for medical imaging, including a needle guide comprising a pair of plates (Fig. 17), each comprising a pattern of radiopaque markers (89, radiopaque lines). Wolf et al. (US 2022/0142730 A1) discloses a medical marking device (abstract) comprising a radiotransparent plate having a plurality of radiopaque elements embedded therein in a predefined pattern (par. [0022]). Eslami et al. (US 2020/0397370 A1) discloses a system for locating a position in a body (abstract) comprising two sets of radiopaque markers on a first and second longitudinal axis (par. [0004]). Izmirli et al. (US 2019/0328482 A1) discloses a registration plate for use with a medical imaging system for calculation of a position in a 3D and 2D coordinate system (abstract) comprising a plurality of fiducial markers in predefined patterns (par. [0033], Fig. 6-9). With respect to claims 1 and 9, the cited prior art does not appear to disclose or reasonably suggest: an orientation plate attached to a base frame and having a first set of radiopaque markers arranged along at least four radial lines which extend from a center location, the radial lines are angularly spaced apart about the center location, and at least three of the radiopaque markers are arranged along each of the radial lines; and a registration plate attached to the base frame and spaced apart from the orientation plate, the registration plate having a second set of radiopaque markers, as claimed. Claims 2-8 are allowable for reasons of dependency. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARK R GAWORECKI whose telephone number is (571)272-8540. The examiner can normally be reached Monday-Friday 8 AM-6 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, DAVID MAKIYA can be reached at 571-272-2273. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARK R GAWORECKI/Primary Examiner, Art Unit 2884 10 February 2026
Read full office action

Prosecution Timeline

Aug 06, 2024
Application Filed
Feb 10, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12603266
DEVICE AND METHOD FOR HIGH POWER-DENSITY THERMIONIC ENERGY CONVERSION
2y 5m to grant Granted Apr 14, 2026
Patent 12597581
X-RAY GENERATION DEVICE
2y 5m to grant Granted Apr 07, 2026
Patent 12591075
RADIATION DETECTOR, METHOD FOR MANUFACTURING RADIATION DETECTOR, AND IMAGING METHOD
2y 5m to grant Granted Mar 31, 2026
Patent 12586672
INTELLIGENT TREATABLE SECTORS FOR RADIATION THERAPY PLAN GENERATION
2y 5m to grant Granted Mar 24, 2026
Patent 12582317
DETECTING DEVICE AND MEASURING APPARATUS
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
91%
Grant Probability
98%
With Interview (+6.6%)
2y 1m
Median Time to Grant
Low
PTA Risk
Based on 1128 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month